MONOCLONAL AB A-33 TO STAGE COLORECTAL CANCER PATIENTS

单克隆 AB A-33 用于对结直肠癌患者进行分期

• 批准号: 3204916
• 负责人: ALFRED M. COHEN
• 金额: $ 16.19万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-08-01 至 1996-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3204916
• 关键词: bone marrow; colorectal neoplasms; gamma radiation; hepatectomy; histopathology; human subject; immunocytochemistry; immunoglobulin G; iodine; liver neoplasms; metastasis; monoclonal antibody; neoplasm /cancer classification /staging; neoplasm /cancer immunodiagnosis; neoplasm /cancer relapse /recurrence; radioimmunoassay; radiotracer; scintillation cameras; tumor antigens

The objective of this Interactive R01 (I-R01) submitted in response to the RFA: CA-92-25 is to improve the longterm survival of patients with colorectal cancer metastatic to the liver and to avoid inappropriate treatment programs. This will be accomplished by collaboration amongst the clinical chemotherapy trials (Kemeny I-R01, IRPG Coordinator), studies of drug resistance (Bertino I-R01), and our Studies. The overall goal of this application is to utilize a monoclonal antibody strategy for more accurate Staging by the detection of occult metastatic cancer in patients with clinically isolated hepatic metastases entered into programs under the Kemeny I-R01 clinical trials. We will also obtain operative specimens from this patient population for laboratory study under the Bertino I-R01. Our program will focus on the utilization of the monoclonal antibody A- 33, developed at our institution. The associated antigen is a large molecular weight cell surface glycoprotein that is not secreted into the bloodstream, and the antibody is rapidly internalized after complexing. The patients have clinically isolated hepatic metastases undergoing surgery for hepatic resection or for hepatic artery pump placement for unresectable disease (Kemeny I-R01). Our projects include (1) the detection of occult bone marrow metastases, (2) intraoperative radioimmunodetection with a gamma detecting probe and an innovative intraoperative gamma camera, (3) immunobiological specificity of MAB nodal uptake, and (4) studies with murine IgG and humanized IgG/fragments. The failure to detect occult bone marrow or intra- abdominal extrahepatic metastatic cancer should maximize long-term survival of patients undergoing hepatic resection of hepatic artery chemotherapy. The positive detection of occult extrahepatic disease will avoid inappropriate treatment in such patients.

本交互式R 01（I-R 01）的目标是为了响应 RFA：CA-92-25旨在改善患有以下疾病的患者的长期生存率： 结直肠癌转移到肝脏，并避免不适当的 治疗方案。 这将通过以下方面的合作来实现： 临床化疗试验（Kemeny I-R 01，IRPG协调员）， 耐药性研究（Bertino I-R 01）和我们的研究。 整体 本申请的目的是利用单克隆抗体策略， 通过检测隐匿性转移癌， 临床孤立性肝转移患者入组 在Kemeny I-R 01临床试验下的项目。 我们还将获得 用于实验室研究的患者人群手术标本 在Bertino I-R 01下 我们的计划将集中在利用单克隆抗体A- 33、在我们的学校里， 相关抗原是一种大的 分子量的细胞表面糖蛋白，不分泌到 血液中，抗体在复合后迅速内化。 患者具有临床孤立的肝转移， 肝切除术或肝动脉泵植入术 不可切除的疾病（Kemeny I-R 01）。 我们的项目包括（1） 检测隐匿性骨髓转移，（2）术中 放射免疫检测与伽玛检测探针和创新的 术中γ照相;（3）MAB的免疫生物学特异性 结节摄取，和（4）用鼠IgG和人源化IgG的研究 IgG/片段。 无法检测到隐匿的骨髓或内- 腹部肝外转移癌应最大限度地长期 肝动脉切除术患者的生存率 化疗 隐匿性肝外疾病的阳性检测将 避免对此类患者进行不当治疗。